Mengyu Li
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Mengyu Li has a total of 11 co-authors. Here are the top co-authors by number of shared publications:
- Hak-Kim Chan
The University of Sydney
2 shared publications - Michael Yee Tak Chow
Advanced Drug Delivery Group, Faculty of Medicine and Health, School of Pharmacy, The University of Sydney, Sydney, New South Wales, Australia
2 shared publications - Rachel Yoon Kyung Chang
Advanced Drug Delivery Group, The University of Sydney, Faculty of Medicine and Health, School of Pharmacy, Sydney, New South Wales, Australia
2 shared publications - Andrew J. McLachlan
Sydney Pharmacy School, Faculty of Medicine and Health University of Sydney Sydney New South Wales Australia
1 shared publication Elizabeth Kutter
The Evergreen State College, Olympia, Washington 98502, USA; EK
1 shared publication- Jian Li
Biomedicine Discovery Institute, Infection Program, Monash University
1 shared publication
Latest Publications
- 18 March 2022
- Published by Elsevier in European Journal of Pharmaceutics and Biopharmaceutics
- Vol. 173, 132-140
A dual action of D-amino acids on anti-biofilm activity and moisture-protection of inhalable ciprofloxacin powders
- 18 March 2022
- Published by Elsevier in European Journal of Pharmaceutics and Biopharmaceutics
- Vol. 173, 132-140
A dual action of D-amino acids on anti-biofilm activity and moisture-protection of inhalable ciprofloxacin powders
- Open Access
Pharmacokinetics and pharmacodynamics of inhaled antipseudomonal bacteriophage therapy in mice
Inhaled bacteriophage (phage) therapy is a potential alternative to conventional antibiotic therapy to combat multidrug-resistant (MDR) Pseudomonas aeruginosa infections. However, pharmacokinetics (PK) and pharmacodynamics (PD) of phages are fundamentally different to antibiotics and the lack of understanding potentially limits optimal dosing. The aim of this study was to investigate the in vivo PK and PD profiles of antipseudomonal phage PEV31 delivered by pulmonary route in mice. BALB/c mice were administered phage PEV31 at doses of 10 7 and 10 9 PFU by the intratracheal route. Mice ( n = 4) were sacrificed at 0, 1, 2, 4, 8 and 24 h post-treatment and various tissues (lungs, kidney, spleen and liver), bronchoalveolar lavage and blood were collected for phage quantification. In a separate study, mice ( n = 4) were treated with PEV31 (10 9 PFU) or PBS at 2 h post-inoculation with MDR P. aeruginosa . Infective PEV31 and bacteria were enumerated from the lungs. In the phage only study, PEV31 titer gradually decreased in the lungs over 24 hours with a half-life of approximately 8 h for both doses. In the presence of bacteria, PEV31 titer increased by almost 2-log 10 in the lungs at 16 h. Furthermore, bacterial growth was suppressed in the PEV31-treated group, while the PBS-treated group showed exponential growth. Some phage-resistant colonies were observed from the lung homogenates sampled at 24 h post-phage treatment. These colonies had a different antibiogram to the parent bacteria. This study provides evidence that pulmonary delivery of phage PEV31 in mice can reduce the MDR bacterial burden.
Open AccessPharmacokinetics and pharmacodynamics of inhaled antipseudomonal bacteriophage therapy in mice
Inhaled bacteriophage (phage) therapy is a potential alternative to conventional antibiotic therapy to combat multidrug-resistant (MDR) Pseudomonas aeruginosa infections. However, pharmacokinetics (PK) and pharmacodynamics (PD) of phages are fundamentally different to antibiotics and the lack of understanding potentially limits optimal dosing. The aim of this study was to investigate the in vivo PK and PD profiles of antipseudomonal phage PEV31 delivered by pulmonary route in mice. BALB/c mice were administered phage PEV31 at doses of 10 7 and 10 9 PFU by the intratracheal route. Mice ( n = 4) were sacrificed at 0, 1, 2, 4, 8 and 24 h post-treatment and various tissues (lungs, kidney, spleen and liver), bronchoalveolar lavage and blood were collected for phage quantification. In a separate study, mice ( n = 4) were treated with PEV31 (10 9 PFU) or PBS at 2 h post-inoculation with MDR P. aeruginosa . Infective PEV31 and bacteria were enumerated from the lungs. In the phage only study, PEV31 titer gradually decreased in the lungs over 24 hours with a half-life of approximately 8 h for both doses. In the presence of bacteria, PEV31 titer increased by almost 2-log 10 in the lungs at 16 h. Furthermore, bacterial growth was suppressed in the PEV31-treated group, while the PBS-treated group showed exponential growth. Some phage-resistant colonies were observed from the lung homogenates sampled at 24 h post-phage treatment. These colonies had a different antibiogram to the parent bacteria. This study provides evidence that pulmonary delivery of phage PEV31 in mice can reduce the MDR bacterial burden.